Status:

COMPLETED

Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia

Lead Sponsor:

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conditions:

Hypertension

Hyperlipidemia

Eligibility:

All Genders

18-75 years

Phase:

PHASE4

Brief Summary

To evaluate efficacy of the dual therapy of atorvastatin + amlodipine vs. amlodipine alone .

Eligibility Criteria

Inclusion

  • Subjects with a diagnosis of both hyperlipidemia and hypertension.

Exclusion

  • Subjects with Type 1 diabetes mellitus or Type 2 diabetes mellitus.
  • Subjects with other atherosclerotic disease.

Key Trial Info

Start Date :

May 1 2005

Trial Type :

INTERVENTIONAL

End Date :

February 1 2006

Estimated Enrollment :

330 Patients enrolled

Trial Details

Trial ID

NCT00174330

Start Date

May 1 2005

End Date

February 1 2006

Last Update

January 27 2021

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

Pfizer Investigational Site

Beijing, Beijing Municipality, China, 100044

2

Pfizer Investigational Site

Guangzhou, Guangdong, China, 510080

3

Pfizer Investigational Site

Guangzhou, Guangdong, China, 510100

4

Pfizer Investigational Site

Guangzhou, Guangdong, China, 510515